Genprex Balance Sheet Health
Financial Health criteria checks 3/6
Genprex has a total shareholder equity of $1.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $3.9M and $2.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$1.49m |
Equity | US$1.66m |
Total liabilities | US$2.24m |
Total assets | US$3.91m |
Recent financial health updates
Recent updates
Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?
Aug 16Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation
Jan 31Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans
Oct 12Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer
Aug 15We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate
Jun 14Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation
Feb 09Genprex: Limited Clinical Data To Justify Risk
Nov 19We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth
Oct 27Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans
Jun 11Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%
May 05Genprex' stock jumps after corporate update
Feb 01Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials
Jan 13Genprex completes manufacturing scale-up of lung cancer therapy
Dec 22Financial Position Analysis
Short Term Liabilities: GNPX's short term assets ($1.9M) do not cover its short term liabilities ($2.2M).
Long Term Liabilities: GNPX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: GNPX is debt free.
Reducing Debt: GNPX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GNPX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GNPX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 19.2% each year
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/12 04:02 |
End of Day Share Price | 2025/01/10 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genprex, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
James Molloy | Alliance Global Partners |